Sort   by:  
 Page size 
UnknownRadical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Importance:The optimal treatment for Gleason score 9-10 prostate cancer is unknown. Objective:To compare clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Design, Setting, and Participants:Retrospective cohort study in 12 tertiary centers (11 in the Un...
S-EPMC5885899 | biostudies-literature
UnknownComparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features.

Importance

The optimal management strategy for high-risk prostate cancer and additional adverse clinicopathologic features remains unknown.

Objective

To compare clinical outcomes among patients with high-risk prostate cancer after definitive treatment.

Design, setting, and particip...

S-EPMC8251338 | biostudies-literature
UnknownInterplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.

Importance

Radiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and the required minimum duration of ADT is uncertain.

Objective

To determine the specific ADT duration thresh...
S-EPMC8778608 | biostudies-literature
UnknownPatterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer.
The natural history of radiorecurrent high-risk prostate cancer (HRPCa) is not well-described. To better understand its clinical course, we evaluated rates of distant metastases (DM) and prostate cancer-specific mortality (PCSM) in a cohort of 978 men with radiorecurrent HRPCa who previously receive...
S-EPMC10262978 | biostudies-literature
UnknownPerformance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.

Importance

Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect low-volume, nonlocalized (ie, regional or metastatic) prostate cancer that was occult on conventional imaging. However, the long-term clinical implications of PSMA PET/CT...
S-EPMC8669522 | biostudies-literature
UnknownAnalyzing Potential Non-Ignorable Selection Bias in an Off-Wave Mail Survey Implemented in a Long-Standing Panel Study.
Typical design-based methods for weighting probability samples rely on several assumptions, including the random selection of sampled units according to known probabilities of selection and ignorable unit nonresponse. If any of these assumptions are not met, weighting methods that account for the pr...
S-EPMC11770253 | biostudies-literature
UnknownThe anchoring method: Estimation of interviewer effects in the absence of interpenetrated sample assignment.
Methodological studies of the effects that human interviewers have on the quality of survey data have long been limited by a critical assumption: that interviewers in a given survey are assigned random subsets of the larger overall sample (also known as interpenetrated assignment). Absent this type ...
S-EPMC9983757 | biostudies-literature
UnknownIncorporating Adaptive Survey Design in a Two-Stage National Web or Mail Mixed-Mode Survey: An Experiment in the American Family Health Study.
This article presents the results of an adaptive design experiment in the recruitment of households and individuals for a two-stage national probability web or mail mixed-mode survey, the American Family Health Study (AFHS). In the screening stage, we based the adaptive design's subgroup differentia...
S-EPMC11189656 | biostudies-literature
UnknownInterim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Background

Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.

Objective

To report the utility of PSA screening, Pr...
S-EPMC6880781 | biostudies-literature
UnknownImplementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Purpose

Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alterna...
S-EPMC7430215 | biostudies-literature
Sort   by:  
 Page size